financetom
Business
financetom
/
Business
/
Update: Microsoft Files Motion to Dismiss Three Contentions in New York Times Lawsuit Over AI
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Update: Microsoft Files Motion to Dismiss Three Contentions in New York Times Lawsuit Over AI
Mar 7, 2024 3:13 AM

05:50 AM EST, 03/07/2024 (MT Newswires) -- (Updates last paragraph with a comment from Microsoft ( MSFT ).)

Microsoft ( MSFT ) filed a motion Monday to dismiss parts of a lawsuit filed by The New York Times Company ( NYT ) alleging copyright infringement by Microsoft ( MSFT ) and its partner OpenAI.

In its motion, Microsoft ( MSFT ) asks the court to dismiss The New York Times' ( NYT ) contentions that Microsoft ( MSFT ) is liable for any end-user copyright infringement, that it violated provisions of the Digital Millennium Copyright Act, and that tools like ChatGPT appropriate time-sensitive news.

Microsoft ( MSFT ) argued in its motion that artificial intelligence tools do not damage the market prospects of news organizations, comparing them to videocassette recording technologies that emerged in the 1970s. "Content used to train Large Language Models does not supplant the market for the works, it teaches the models language," the motion says.

In a statement published by The New York Times ( NYT ), an attorney for the company noted that the motion did not dispute the claim that Microsoft ( MSFT ) and OpenAI copied the news outlet's works without permission to build their tools. "Instead, it oddly compares large language models to the VCR even though VCR makers never argued that it was necessary to engage in massive copyright infringement to build their products," said the attorney.

"Lawfully developed AI-powered tools should be allowed to advance responsibly just like valuable technologies of the past. They are also not a substitute for the vital role that journalists play in our society," a Microsoft ( MSFT ) spokesperson said in an email to MT Newswires.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Concentrix Fiscal Q3 Earnings, Revenue Rise; FY EPS Guidance Cut; Shares Fall After Hours
Concentrix Fiscal Q3 Earnings, Revenue Rise; FY EPS Guidance Cut; Shares Fall After Hours
Oct 3, 2024
05:49 PM EDT, 09/25/2024 (MT Newswires) -- Concentrix ( CNXC ) reported fiscal Q3 non-GAAP earnings Wednesday of $2.87 per diluted share, up from $2.76 a year earlier. Four analysts polled by Capital IQ expected $2.93. Sales for the quarter ended Aug. 31 rose to $2.39 billion from $1.63 billion a year earlier. Four analysts surveyed by Capital IQ expected...
CSL gets $121 mln contract to increase US stockpile for bird flu vaccines to 40 mln doses
CSL gets $121 mln contract to increase US stockpile for bird flu vaccines to 40 mln doses
Oct 3, 2024
Sept 25 (Reuters) - Australia's CSL said on Wednesday it has got a contract from the U.S. Department of Health and Human Services (HHS) worth $121.4 million to increase the U.S. government's stockpile for bird flu vaccines to 40 million doses. Under the multi-year contract CSL will deliver its MF59 adjuvant, an ingredient that can be used to manufacture vaccines...
--American Outdoor Brands Gets Board Authorization for $10 Million Share Repurchase Program Ending Sept. 30 Next Year
--American Outdoor Brands Gets Board Authorization for $10 Million Share Repurchase Program Ending Sept. 30 Next Year
Oct 3, 2024
05:50 PM EDT, 09/25/2024 (MT Newswires) -- Price: 9.01, Change: +0.32, Percent Change: +3.68 ...
Telesis Bio, Beckman Coulter Form Partnership on DNA Synthesis Tech -- Shares Rise After Hours
Telesis Bio, Beckman Coulter Form Partnership on DNA Synthesis Tech -- Shares Rise After Hours
Oct 3, 2024
05:57 PM EDT, 09/25/2024 (MT Newswires) -- Telesis Bio ( TBIO ) said late Wednesday it formed a partnership with Beckman Coulter Life Sciences to create scalable biofoundries, with the goal of delivering solutions for sustainable and rapid on-premise DNA synthesis. The partnership provides an open solution to the market, allowing the incorporation of constructs from other providers compatible with...
Copyright 2023-2026 - www.financetom.com All Rights Reserved